Joint Formulary & PAD

Salbutamol (Salbulin Novolizer) - Asthma

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Inhaler (dry powder)
Associated Icons :
Restrictions / Comments :
Preferred

PAD Profile

ChemicalSubstance :
Salbutamol (Salbulin Novolizer)
Indication :
Asthma
Group Name :
SABA
Keywords :
Salbutamol inhalers, SABAs, bronchodilators, adrenoreceptor agonists, short acting beta 2 agonists, respiratory, reliver inhalers
Brand Names Include :
Salbulin Novolizer
Important Information :

Easyhaler Salbutamol is preferred. Ventolin Accuhaler is a suitable low-carbon alternative DPI.

Not for initiation in new patients.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Salbutamol (Salbulin Novolizer) is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Asthma.

Committee Recommendations (1)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve the use of Ventolin Accuhaler as a treatment option in the management of asthma & COPD.

Ventolin Accuhaler and Salbutamol Easyhaler are the locally preferred dry powder devices.

Salamol MDI is the locally preferred salbutamol MDI device and should be used with a spacer device.
It has a lower carbon footprint than the large volume MDIs such as Ventolin.

Branded prescribing of inhaler devices is recommended.

See local guidelines below